Helius Medical's Neuromodulation Stimulator Nabs FDA Breakthrough Tag

by Vandana Singh, Benzinga Editor

August 17, 2021 8:00 AM | 1 min read | Make a Comment

The FDA has granted Breakthrough Device Designation to Helius Medical Technologies Inc's HSDT PoNS device.
Related content: Benzinga's Full FDA Calendar.
The designation covers the device for use as a temporary treatment of dynamic gait and balance deficits due to stroke as an adjunct to a therapeutic exercise program in patients 22 years of age and over.
PoNS, a portable neuromodulation stimulator, is a non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the tongue's surface to treat gait deficit.
Price Action: HSDT shares are up 10.7% at $15.90 during the premarket session on the last check Tuesday.

Posted In: Long Ideas News Health Care FDA Movers Trading Ideas General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.